Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-10-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
北京市君泽君（深圳）律师事务所关于特一药业集团股份有限公司2021年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of the convening, attendance, and voting procedures of a company's 2021 first extraordinary general meeting (临时股东大会). It details the meeting's notice, attendance, voting results, and confirms compliance with relevant laws and company articles. It is not a report of financial results, audit, or management discussion, nor is it an announcement of voting results in a formal shareholder vote announcement format. Instead, it is a legal opinion on the conduct and validity of the shareholders' meeting. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal attestation related to corporate governance and shareholder meeting procedures, not the meeting materials themselves (AGM-R) or voting results announcement (DVA). The document length is under 5,000 characters and is a standalone legal opinion letter, not a report or announcement of a report publication.
2021-10-28 Chinese
关于2021年股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading related to a 2021 stock option incentive plan. It details the investigation of insider and incentive object stock transactions during a specific period, referencing regulatory compliance and internal controls. The document is a formal announcement of the results of this internal investigation and does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual or interim report, nor a call transcript or capital update. It is a regulatory disclosure related to insider trading compliance and stock option incentive plans. Given the nature and length (1652 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-28 Chinese
监事会关于公司2021年股票期权激励计划激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement from the supervisory board (监事会) of 特一药业集团股份有限公司 regarding the review and public disclosure of the list of incentive recipients under the company's 2021 stock option incentive plan. It includes details about the public notice period, the review process, and the supervisory board's opinion confirming the legitimacy and compliance of the incentive recipients. The document does not contain financial statements or detailed financial data, nor is it a report like an annual or interim report. It is a regulatory announcement related to stock option incentive plan participants and their compliance with relevant regulations. This fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories such as capital changes or remuneration reports.
2021-10-22 Chinese
关于公司药品复方磺胺甲噁唑片通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product's consistency evaluation by the National Medical Products Administration. It includes details about the drug, its regulatory approval, and the impact on the company. The document is short (1188 characters) and does not contain financial statements, earnings data, or management discussion. It is not a report but an announcement about a regulatory approval related to the company's product. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-21 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the third quarter of 2021. The document explicitly states it is a quarterly report and mentions it is unaudited. The length is over 12,000 characters, indicating it is a full report rather than a brief announcement. The content matches the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. 9M 2021
2021-10-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed by the Supervisory Board regarding the review and approval of the company's 2021 third quarter report. It states that the Supervisory Board has reviewed the procedures and content of the third quarter report and found them compliant and accurate. The document is short (625 characters) and does not contain the actual financial statements or substantive financial data of the third quarter report itself, but rather the approval and confirmation of that report by the Supervisory Board. Therefore, this document is not the interim/quarterly report itself but an announcement related to it. Given the nature of the content, it fits best under Regulatory Filings (RNS) as a compliance announcement rather than the full interim report (IR).
2021-10-18 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.